## Amit V Khera

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/734678/publications.pdf

Version: 2024-02-01

		28190	19136
119	20,342	55	118
papers	citations	h-index	g-index
139	139	139	25985
all docs	docs citations	times ranked	citing authors

#	Article	IF	CITATIONS
1	Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics, 2018, 50, 1219-1224.	9.4	2,111
2	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation, 2019, 140, e596-e646.	1.6	1,789
3	Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis. New England Journal of Medicine, 2011, 364, 127-135.	13.9	1,686
4	Mendelian Randomization. JAMA - Journal of the American Medical Association, 2017, 318, 1925.	3.8	1,253
5	Genetic Risk, Adherence to a Healthy Lifestyle, and Coronary Disease. New England Journal of Medicine, 2016, 375, 2349-2358.	13.9	979
6	2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary. Journal of the American College of Cardiology, 2019, 74, 1376-1414.	1.2	820
7	Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia. Journal of the American College of Cardiology, 2016, 67, 2578-2589.	1.2	723
8	A structural variation reference for medical and population genetics. Nature, 2020, 581, 444-451.	13.7	614
9	Polygenic Prediction of Weight and Obesity Trajectories from Birth to Adulthood. Cell, 2019, 177, 587-596.e9.	13.5	516
10	Genetics of blood lipids among ~300,000 multi-ethnic participants of the Million Veteran Program. Nature Genetics, 2018, 50, 1514-1523.	9.4	497
11	Exome-wide association study of plasma lipids in >300,000 individuals. Nature Genetics, 2017, 49, 1758-1766.	9.4	470
12	Genetics of coronary artery disease: discovery, biology and clinical translation. Nature Reviews Genetics, 2017, 18, 331-344.	7.7	448
13	Monkeys Pay Per View: Adaptive Valuation of Social Images by Rhesus Macaques. Current Biology, 2005, 15, 543-548.	1.8	361
14	A Genetic Variant Associated with Five Vascular Diseases Is a Distal Regulator of Endothelin-1 Gene Expression. Cell, 2017, 170, 522-533.e15.	13.5	356
15	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. Obesity, 2013, 21, E439-47.	1.5	355
16	The power of genetic diversity in genome-wide association studies of lipids. Nature, 2021, 600, 675-679.	13.7	353
17	ANGPTL3 Deficiency and Protection Against Coronary Artery Disease. Journal of the American College of Cardiology, 2017, 69, 2054-2063.	1.2	348
18	Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk. Circulation, 2014, 129, 635-642.	1.6	338

#	Article	IF	CITATIONS
19	Genetic Association of Waist-to-Hip Ratio With Cardiometabolic Traits, Type 2 Diabetes, and Coronary Heart Disease. JAMA - Journal of the American Medical Association, 2017, 317, 626.	3.8	313
20	Polygenic background modifies penetrance of monogenic variants for tier $1$ genomic conditions. Nature Communications, 2020, $11$ , 3635.	5.8	277
21	A single-cell atlas of human and mouse white adipose tissue. Nature, 2022, 603, 926-933.	13.7	277
22	Improving reporting standards for polygenic scores in risk prediction studies. Nature, 2021, 591, 211-219.	13.7	265
23	Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction. Circulation, 2019, 139, 1593-1602.	1.6	213
24	Genetic analysis in UK Biobank links insulin resistance and transendothelial migration pathways to coronary artery disease. Nature Genetics, 2017, 49, 1392-1397.	9.4	190
25	Phenotypic Characterization of GeneticallyÂLowered Human Lipoprotein(a) Levels. Journal of the American College of Cardiology, 2016, 68, 2761-2772.	1.2	186
26	Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events. Circulation, 2017, 135, 2494-2504.	1.6	180
27	Association of Rare and Common Variation in the Lipoprotein Lipase Gene With Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2017, 317, 937.	3.8	148
28	Polygenic basis and biomedical consequences of telomere length variation. Nature Genetics, 2021, 53, 1425-1433.	9.4	145
29	Deep-coverage whole genome sequences and blood lipids among 16,324 individuals. Nature Communications, 2018, 9, 3391.	5.8	140
30	Analysis of cardiac magnetic resonance imaging in 36,000 individuals yields genetic insights into dilated cardiomyopathy. Nature Communications, 2020, 11, 2254.	5.8	140
31	Association of Habitual Alcohol Intake With Risk of Cardiovascular Disease. JAMA Network Open, 2022, 5, e223849.	2.8	136
32	Effect of Right Ventricular Function and Venous Congestion on Cardiorenal Interactions During the Treatment of Decompensated Heart Failure. American Journal of Cardiology, 2010, 105, 511-516.	0.7	120
33	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. Circulation, 2009, 119, 1711-1719.	1.6	117
34	Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies. European Heart Journal, 2021, 42, 3388-3403.	1.0	114
35	Body Fat Distribution and Incident Cardiovascular Disease in Obese Adults. Journal of the American College of Cardiology, 2015, 65, 2150-2151.	1.2	113
36	Leveraging fine-mapping and multipopulation training data to improve cross-population polygenic risk scores. Nature Genetics, 2022, 54, 450-458.	9.4	109

#	Article	IF	Citations
37	The Anti-Oxidative Capacity of High-Density Lipoprotein Is Reduced in Acute Coronary Syndrome But Not in Stable Coronary Artery Disease. Journal of the American College of Cardiology, 2011, 58, 2068-2075.	1.2	105
38	Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2021, 41, 465-474.	1.1	104
39	Race, socioeconomic deprivation, and hospitalization for COVID-19 in English participants of a national biobank. International Journal for Equity in Health, 2020, 19, 114.	1.5	101
40	A missense variant in Mitochondrial Amidoxime Reducing Component 1 gene and protection against liver disease. PLoS Genetics, 2020, 16, e1008629.	1.5	101
41	Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes. Nature Communications, 2018, 9, 2252.	5.8	99
42	Future Therapeutic Directions in Reverse Cholesterol Transport. Current Atherosclerosis Reports, 2010, 12, 73-81.	2.0	93
43	Limitations of Contemporary Guidelines for Managing Patients at High Genetic Risk of Coronary Artery Disease. Journal of the American College of Cardiology, 2020, 75, 2769-2780.	1.2	88
44	Phenotypic Consequences of a Genetic Predisposition to Enhanced Nitric Oxide Signaling. Circulation, 2018, 137, 222-232.	1.6	87
45	Monogenic and Polygenic Contributions to Atrial Fibrillation Risk. Circulation Research, 2020, 126, 200-209.	2.0	79
46	Analysis of predicted loss-of-function variants in UK Biobank identifies variants protective for disease. Nature Communications, 2018, 9, 1613.	5.8	78
47	Validation of a Genome-Wide PolygenicÂScore for Coronary ArteryÂDisease inÂSouth Asians. Journal of the American College of Cardiology, 2020, 76, 703-714.	1.2	76
48	Association of Rare Pathogenic DNA Variants for Familial Hypercholesterolemia, Hereditary Breast and Ovarian Cancer Syndrome, and Lynch Syndrome With Disease Risk in Adults According to Family History. JAMA Network Open, 2020, 3, e203959.	2.8	75
49	Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals. Circulation, 2021, 144, 410-422.	1.6	72
50	Dense Genotyping of Candidate Gene Loci Identifies Variants Associated With High-Density Lipoprotein Cholesterol. Circulation: Cardiovascular Genetics, 2011, 4, 145-155.	5.1	71
51	The Addition of Niacin to Statin Therapy Improves High-Density Lipoprotein Cholesterol Levels ButÂNot Metrics of Functionality. Journal of the American College of Cardiology, 2013, 62, 1909-1910.	1.2	71
52	Genome-Wide Polygenic Score, Clinical Risk Factors, and Long-Term Trajectories of Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2020, 40, 2738-2746.	1.1	71
53	Low coverage whole genome sequencing enables accurate assessment of common variants and calculation of genome-wide polygenic scores. Genome Medicine, 2019, 11, 74.	3.6	70
54	Protein-Truncating Variants at the Cholesteryl Ester Transfer Protein Gene and Risk for Coronary Heart Disease. Circulation Research, 2017, 121, 81-88.	2.0	68

#	Article	IF	Citations
55	Association of Genetic Variation With Cirrhosis: A Multi-Trait Genome-Wide Association and Gene–Environment Interaction Study. Gastroenterology, 2021, 160, 1620-1633.e13.	0.6	68
56	A multiancestry genome-wide association study of unexplained chronic ALT elevation as a proxy for nonalcoholic fatty liver disease with histological and radiological validation. Nature Genetics, 2022, 54, 761-771.	9.4	68
57	The novel atherosclerosis locus at 10q11 regulates plasma CXCL12 levels. European Heart Journal, 2011, 32, 963-971.	1.0	67
58	Accuracy of Noninvasively Determined Pulmonary Artery Systolic Pressure. American Journal of Cardiology, 2010, 105, 1192-1197.	0.7	60
59	Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1880-1888.	1.1	60
60	Rare Protein-Truncating Variants in <i>APOB</i> , Lower Low-Density Lipoprotein Cholesterol, and Protection Against Coronary Heart Disease. Circulation Genomic and Precision Medicine, 2019, 12, e002376.	1.6	57
61	Electronic health record-based genome-wide meta-analysis provides insights on the genetic architecture of non-alcoholic fatty liver disease. Cell Reports Medicine, 2021, 2, 100437.	3.3	56
62	Effects of Niacin, Statin, and Fenofibrate on Circulating Proprotein Convertase Subtilisin/Kexin Type 9 Levels in Patients With Dyslipidemia. American Journal of Cardiology, 2015, 115, 178-182.	0.7	51
63	Anti-oxidative and cholesterol efflux capacities of high-density lipoprotein are reduced in ischaemic cardiomyopathy. European Journal of Heart Failure, 2013, 15, 1215-1219.	2.9	49
64	Heterozygous <i> ABCG5 &lt; /i &gt; Gene Deficiency and Risk of Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2020, 13, 417-423.</i>	1.6	45
65	Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases. Nature Metabolism, 2021, 3, 1476-1483.	5.1	43
66	Inherited basis of visceral, abdominal subcutaneous and gluteofemoral fat depots. Nature Communications, 2022, 13, .	5.8	43
67	On-Statin Cholesteryl Ester Transfer Protein Mass and Risk of Recurrent Coronary Events (from the) Tj ETQq1 1 (	0.784314 i 0.7	rgBT /Overloo 37
68	Is Coronary Atherosclerosis One Disease or Many?. Circulation, 2017, 135, 1005-1007.	1.6	36
69	Genetic Association of Finger Photoplethysmography-Derived Arterial Stiffness Index With Blood Pressure and Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1253-1261.	1.1	35
70	What Is Familial Hypercholesterolemia, and Why Does It Matter?. Circulation, 2020, 141, 1760-1763.	1.6	34
71	Machine learning enables new insights into genetic contributions to liver fat accumulation. Cell Genomics, 2021, 1, 100066.	3.0	34
72	Leveraging Human Genetics to Estimate Clinical Risk Reductions Achievable by Inhibiting Factor XI. Stroke, 2019, 50, 3004-3012.	1.0	31

#	Article	IF	Citations
73	DNA Sequence Variation in <i>ACVR1C</i> Encoding the Activin Receptor-Like Kinase 7 Influences Body Fat Distribution and Protects Against Type 2 Diabetes. Diabetes, 2019, 68, 226-234.	0.3	31
74	Cholesterol Efflux Capacity. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1449-1451.	1.1	30
75	Performance of Atrial Fibrillation Risk Prediction Models in Over 4 Million Individuals. Circulation: Arrhythmia and Electrophysiology, 2021, 14, e008997.	2.1	30
76	Potent peroxisome proliferator-activated receptor-Â agonist treatment increases cholesterol efflux capacity in humans with the metabolic syndrome. European Heart Journal, 2015, 36, 3020-3022.	1.0	29
77	Evaluation of the Pooled Cohort Equations for Prediction of Cardiovascular Risk in a Contemporary Prospective Cohort. American Journal of Cardiology, 2017, 119, 881-885.	0.7	29
78	Design and user experience testing of a polygenic score report: a qualitative study of prospective users. BMC Medical Genomics, 2021, 14, 238.	0.7	29
79	Rare Genetic Variants Associated With Sudden Cardiac Death in Adults. Journal of the American College of Cardiology, 2019, 74, 2623-2634.	1.2	27
80	Transethnic Transferability of a Genome-Wide Polygenic Score for Coronary Artery Disease. Circulation Genomic and Precision Medicine, 2021, 14, e003092.	1.6	25
81	Rare coding variants in 35 genes associate with circulating lipid levelsâ€"A multi-ancestry analysis of 170,000 exomes. American Journal of Human Genetics, 2022, 109, 81-96.	2.6	24
82	Titin Truncating Variants in Adults Without Known Congestive HeartÂFailure. Journal of the American College of Cardiology, 2020, 75, 1239-1241.	1.2	22
83	Rare and Common Genetic Variation Underlying the Risk of Hypertrophic Cardiomyopathy in a National Biobank. JAMA Cardiology, 2022, 7, 715.	3.0	22
84	Volanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia. New England Journal of Medicine, 2019, 381, 2582-2584.	13.9	21
85	Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease. Diabetes, 2017, 66, 2310-2315.	0.3	20
86	Discovery and Validation of New Molecular Targets in Treating Dyslipidemia: The Role of Human Genetics. Trends in Cardiovascular Medicine, 2009, 19, 195-201.	2.3	19
87	The potential of polygenic scores to improve cost and efficiency of clinical trials. Nature Communications, 2022, $13$ , .	5.8	19
88	Polyphenols and Cholesterol Efflux. Circulation Research, 2010, 106, 627-629.	2.0	18
89	Selection of 51 predictors from 13,782 candidate multimodal features using machine learning improves coronary artery disease prediction. Patterns, 2021, 2, 100364.	3.1	18
90	Genetic Risk, Lifestyle, and Coronary Artery Disease. New England Journal of Medicine, 2017, 376, 1192-1195.	13.9	17

#	Article	IF	CITATIONS
91	Randomized prospective evaluation of genome sequencing versus standard-of-care as a first molecular diagnostic test. Genetics in Medicine, 2021, 23, 1689-1696.	1.1	17
92	Association of the Interaction Between Familial Hypercholesterolemia Variants and Adherence to a Healthy Lifestyle With Risk of Coronary Artery Disease. JAMA Network Open, 2022, 5, e222687.	2.8	17
93	Concordance of a High Polygenic Score Among Relatives. Circulation Genomic and Precision Medicine, 2021, 14, e003262.	1.6	16
94	Management of Low Levels of High-Density Lipoprotein-Cholesterol. Circulation, 2013, 128, 72-78.	1.6	15
95	Association of Pathogenic DNA Variants Predisposing to Cardiomyopathy With Cardiovascular Disease Outcomes and All-Cause Mortality. JAMA Cardiology, 2022, 7, 723.	3.0	15
96	On-Statin Resistin, Leptin, and Risk of Recurrent Coronary Events After Hospitalization for an Acute Coronary Syndrome (from the Pravastatin or Atorvastatin Evaluation and Infection) Tj ETQq0 0 0 rgBT /Overlock 1694-698.	10,Tf 50 54	12 Td (Thera
97	Genetic Predictor to Identify Individuals With High Lipoprotein(a) Concentrations. Circulation Genomic and Precision Medicine, 2021, 14, e003182.	1.6	10
98	Rare, Damaging DNA Variants in <i>CORIN</i> and Risk of Coronary Artery Disease: Insights From Functional Genomics and Large-Scale Sequencing Analyses. Circulation Genomic and Precision Medicine, 2021, 14, e003399.	1.6	10
99	Polygenic Score Assessed in Young Adulthood and Onset ofÂSubclinical Atherosclerosis and Coronary Heart Disease. Journal of the American College of Cardiology, 2022, 80, 280-282.	1.2	10
100	Physiology as a Lingua Franca for Clinical Machine Learning. Patterns, 2020, 1, 100017.	3.1	9
101	Genome-Wide Polygenic Score and Cardiovascular Outcomes With Evacetrapib in Patients With High-Risk Vascular Disease. Circulation Genomic and Precision Medicine, 2020, 13, e002767.	1.6	9
102	Estimated Yield of Screening for Heterozygous Familial Hypercholesterolemia With and Without Genetic Testing in US Adults. Journal of the American Heart Association, 2022, 11, e025192.	1.6	7
103	The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?. European Journal of Preventive Cardiology, 2016, 23, 1062-1064.	0.8	5
104	Demystifying HDL Cholesterol—A "Human Knockout―to the Rescue?. Clinical Chemistry, 2017, 63, 33-36.	1.5	5
105	Fasting for lipid testing: Is it worth the trouble?. Archives of Internal Medicine, 2012, 172, 1710-2.	4.3	5
106	Response to Letter Regarding Article, "Lipoprotein(a) Concentrations, Rosuvastatin Therapy, and Residual Vascular Risk: An Analysis From the JUPITER Trial (Justification for the Use of Statins in) Tj ETQq0 0 0 rgB <sup>-</sup>	T <b>/10</b> sverlocl	k <b>4</b> 0 Tf 50 1
107	Single-cell transcriptomics: an emerging tool in the study of cardiometabolic disease. Journal of Translational Medicine, 2014, 12, 312.	1.8	4
108	Genetic Predisposition to Abdominal Obesity and Cardiometabolic Riskâ€"Reply. JAMA - Journal of the American Medical Association, 2017, 317, 2334.	3.8	4

#	Article	IF	CITATIONS
109	Association of Genome-Wide Polygenic Risk Score for Body Mass Index With Cardiometabolic Health From Childhood Through Midlife. Circulation Genomic and Precision Medicine, 2022, 15, .	1.6	4
110	Electronic Health Record-Based Genome-Wide Meta-Analysis Provides New Insights on the Genetic Architecture of Non-Alcoholic Fatty Liver Disease. SSRN Electronic Journal, 0, , .	0.4	2
111	RARE PROTEIN-TRUNCATING VARIANTS IN APOB ASSOCIATE WITH LOWER LOW-DENSITY LIPOPROTEIN CHOLESTEROL, LOWER TRIGLYCERIDES, AND REDUCED RISK OF CORONARY HEART DISEASE. Journal of the American College of Cardiology, 2019, 73, 1716.	1.2	1
112	Predicting Risk of Hypertension Among Childhood Cancer Survivors. JACC: CardioOncology, 2021, 3, 85-87.	1.7	1
113	Perspectives on Identifying and Treating Familial Hypercholesterolemia in Childhood. Clinical Chemistry, 2021, 67, 1312-1317.	1.5	1
114	$\langle i \rangle$ CYP2C19 $\langle i \rangle$ Genotyping in Anticoagulated Patients After Percutaneous Coronary Intervention: Should It Be Routine?. Circulation, 2022, 145, 721-723.	1.6	1
115	Analyzing human knockouts to validate GPR151 as a therapeutic target for reduction of body mass index. PLoS Genetics, 2022, 18, e1010093.	1.5	1
116	My Most Famous Patient. Academic Medicine, 2008, 83, 1170-1171.	0.8	0
117	B-PO02-164 GENOME-WIDE POLYGENIC RISK SCORE PREDICTS SUDDEN ARRHYTHMIC DEATH IN PATIENTS WITH CORONARY ARTERY DISEASE. Heart Rhythm, 2021, 18, S164-S165.	0.3	0
118	Abdominal subcutaneous adipose tissue negatively associates with subclinical coronary artery disease in men with psoriasis. American Journal of Preventive Cardiology, 2021, 8, 100231.	1.3	0
119	Response by Patel and Khera to Letter Regarding Article, "Quantifying and Understanding the Higher Risk of Atherosclerotic Cardiovascular Disease Among South Asian Individuals: Results From the UK Biobank Prospective Cohort Study― Circulation, 2022, 145, e147-e148.	1.6	0